- Home
- BGLC vs DRCT Comparison
BGLC vs DRCT Comparison
Compare BGLC & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- DRCT
- Stock Information
- Founded
- BGLC 2017
- DRCT 2018
- Country
- BGLC Malaysia
- DRCT United States
- Employees
- BGLC N/A
- DRCT N/A
- Industry
- BGLC Medical Specialities
- DRCT Computer Software: Programming Data Processing
- Sector
- BGLC Health Care
- DRCT Technology
- Exchange
- BGLC Nasdaq
- DRCT Nasdaq
- Market Cap
- BGLC 10.7M
- DRCT 11.4M
- IPO Year
- BGLC N/A
- DRCT 2022
- Fundamental
- Price
- BGLC $5.52
- DRCT $0.43
- Analyst Decision
- BGLC
- DRCT Strong Buy
- Analyst Count
- BGLC 0
- DRCT 1
- Target Price
- BGLC N/A
- DRCT $6.00
- AVG Volume (30 Days)
- BGLC 3.4M
- DRCT 698.4K
- Earning Date
- BGLC 08-18-2025
- DRCT 08-05-2025
- Dividend Yield
- BGLC N/A
- DRCT N/A
- EPS Growth
- BGLC N/A
- DRCT N/A
- EPS
- BGLC N/A
- DRCT N/A
- Revenue
- BGLC $9,265,870.00
- DRCT $36,459,000.00
- Revenue This Year
- BGLC N/A
- DRCT $50.71
- Revenue Next Year
- BGLC N/A
- DRCT $26.31
- P/E Ratio
- BGLC N/A
- DRCT N/A
- Revenue Growth
- BGLC N/A
- DRCT N/A
- 52 Week Low
- BGLC $2.01
- DRCT $0.38
- 52 Week High
- BGLC $15.60
- DRCT $6.59
- Technical
- Relative Strength Index (RSI)
- BGLC 52.81
- DRCT 32.56
- Support Level
- BGLC $5.28
- DRCT $0.38
- Resistance Level
- BGLC $5.85
- DRCT $0.79
- Average True Range (ATR)
- BGLC 0.69
- DRCT 0.06
- MACD
- BGLC -0.07
- DRCT -0.02
- Stochastic Oscillator
- BGLC 29.80
- DRCT 3.16
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.